Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Sirtuins’ Status Less Certain as Study Questions Longevity Effect
26 September 2011. The family of histone deacetylase proteins known as sirtuins have been heralded as keys to longevity, based largely on studies in yeast, flies, and worms. New data now call these findings into question. In the September 22 Nature, researchers led by David Gems at University College London, U.K., report that the lifespan extension seen in the original C. elegans and Drosophila lines that overexpressed Sir2 was due to confounding effects from genetic background and transgene insertion. Repeating the initial experiments with new controls, Gems and colleagues report no effect from Sir2 on lifespan. In contrast, Leonard Guarente and colleagues at Massachusetts Institute of Technology, who did some of the initial Sir2 experiments, contend that, though initial lifespan claims were an overestimate, Sir2 still confers a modest extension. Though the issue remains contentious, the debate does not appear to affect the large body of research showing that sirtuins affect mammalian health and metabolism.

Guarente and colleagues first reported that Sir2 overexpression lengthened worm lifespan by up to 50 percent (see Tissenbaum and Guarente, 2001). Guarente co-chairs the scientific advisory board for Sirtris, a GlaxoSmithKline subsidiary that develops drugs based on sirtuins, and he was co-founder of Elixir Pharmaceuticals, which pursues life-extending therapies. Guarente and colleagues also found that sirtuins mediated the lifespan extension provided by calorie reduction (see, e.g., ARF related news story and ARF news story). Other studies have questioned these findings, however, leading Gems and colleagues to re-analyze the issue.

They outcrossed Sir2-overexpressing C. elegans lines into a new genetic background and found that longevity effects vanished. They traced the initial life extension instead to a sensory neuron gene mutation, many of which are known to affect lifespan (see, e.g., Hsin and Kenyon, 1999). Similarly, the U.K. group found no Sir2 lifespan effect in transgenic flies compared to appropriate controls, and found that Sir2 did not mediate the longevity effects of dietary restriction in flies. In an e-mail to ARF, Gems noted that several independent research groups have replicated these findings, and wrote, “The findings in our paper imply that increased Sir2 levels do not slow aging in worms and flies.”

In a Nature Brief Communication, Guarente and Mohan Viswanathan at MIT agree that the sensory neuron gene mutation contributed much of the lifespan extension seen in the original worm study, but report that even after extensive backcrossing, Sir2 stills lengthens life by 10 to 15 percent. The role of Sir2 in worm longevity is supported by an independent group, Guarente wrote to ARF (see Rizki et al., 2011).

Whether Sir2 does have some influence on lifespan or not, it seems clear at least that sirtuins do not hold the prominent place in longevity research they were formerly accorded. As David Lombard and Scott Pletcher at the University of Michigan, Ann Arbor, wrote in an accompanying News & Views article, “At best, therefore, these papers indicate that Sir2 overexpression is just one of more than 100 genetic manipulations currently known to increase worm and/or fly lifespan to some degree, with many others having larger effects.” The results also highlight the importance of performing adequate backcrossing in genetic studies, Lombard and Pletcher note, suggesting that eight to 10 generations of backcrossing should be the standard in both flies and worms.

What does this mean for the role of sirtuins in mammalian biology? Perhaps nothing. Sirtuins have not shown a longevity effect in mouse studies, for example. But as Carles Cantó at the Nestlé Institute of Health Sciences, Lausanne, Switzerland, and Johan Auwerx at the École Polytechnique Fédérale de Lausanne, note in a second News & Views article, “an overwhelming body of evidence indicates that sirtuins have crucial roles in metabolic homeostasis.” In mammals, the proteins have been reported to prevent metabolic disorders (see ARF related news story), reduce phosphorylated tau (see ARF related news story), and play roles in learning and memory (see ARF related news story and ARF news story), among other things. Other histone deacetylases also affect memory and are potential drug targets in neurodegenerative disease (see, e.g., ARF related news story). Sirtuins also confer neuroprotection in a worm model of Huntington’s disease (see ARF related news story). Cantó and Auwerx suggest, “the metabolic adaptations that SIRT1 induces might indirectly influence mammalian lifespan,” and conclude, “SIRT1 activation remains a promising approach to delaying general age-related physiological decline.”—Madolyn Bowman Rogers.

References:
Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvári M, Piper MD, Hoddinott M, Sutphin GL, Leko V, McElwee JJ, Vazquez-Manrique RP, Orfila AM, Ackerman D, Au C, Vinti G, Riesen M, Howard K, Neri C, Bedalov A, Kaeberlein M, Sóti C, Partridge L, Gems D. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature. 2011 Sep 22;477(7365):482-5. Abstract

Viswanathan M, Guarente L. Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes. Nature. 2011 Sep 22. Abstract

Lombard DB, Pletcher SD. Longevity hits a roadblock. Nature. 2011 Sep 22;477(7365):410-1. Abstract

Cantó C, Auwerx J. Don’t write sirtuins off. Nature. 2011 Sep 22;477(7365):411.

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad